Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urology

M S Litwin1

  • 1University of California, Los Angeles, USA.

JAMA
|June 7, 1995
PubMed
Summary
This summary is machine-generated.

Patient symptom assessment is key for benign prostatic hyperplasia (BPH) evaluation and treatment. Promising immunologic therapies are emerging for metastatic renal cell carcinoma, while prostate cancer opinions vary widely.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry.

BMC urology·2023
Same author

Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.

Prostate cancer and prostatic diseases·2015
Same author

Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system.

Prostate cancer and prostatic diseases·2015
Same author

Updated trends in imaging use in men diagnosed with prostate cancer.

Prostate cancer and prostatic diseases·2014
Same author

Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.

Prostate cancer and prostatic diseases·2012
Same author

From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer.

Prostate cancer and prostatic diseases·2010
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
See all related articles

Area of Science:

  • Urology
  • Oncology
  • Immunotherapy

Background:

  • Benign prostatic hyperplasia (BPH) management emphasizes individualized patient symptom assessment.
  • Prostate cancer treatment strategies and opinions exhibit significant diversity.
  • Immunologic therapies are demonstrating potential in treating metastatic renal cell carcinoma.

Purpose of the Study:

  • To highlight the importance of patient-reported symptoms in guiding BPH evaluation and therapy.
  • To acknowledge the broad spectrum of opinions regarding prostate cancer management.
  • To report on the promising advancements in immunologic treatments for metastatic renal cell carcinoma.

Main Methods:

  • Guideline-based principles for benign prostatic hyperplasia assessment.
  • Review of current perspectives on prostate cancer treatment.

Related Experiment Videos

  • Analysis of emerging data on immunologic therapies for renal cell carcinoma.

    • Main Results:

    • Symptom assessment is the cornerstone of benign prostatic hyperplasia (BPH) guideline recommendations.
    • A wide range of opinions exists concerning prostate cancer management approaches.
    • Immunologic therapies show encouraging results in patients with metastatic renal cell carcinoma.

    Conclusions:

    • Patient-centered symptom evaluation should direct benign prostatic hyperplasia (BPH) care.
    • The field of prostate cancer treatment requires ongoing discussion and research.
    • Immunotherapy represents a promising frontier for metastatic renal cell carcinoma treatment.